Repare Therapeutics Inc (RPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.65 Million) by net assets ($115.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Repare Therapeutics Inc (RPTX) market capitalisation for the company's overall valuation and market capitalisation.
Repare Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Repare Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repare Therapeutics Inc ranked by their cash flow conversion efficiency. Explore RPTX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tirathai Public Company Limited
BK:TRT
|
0.287x |
|
ELEMENT 29 RESOURCES INC
F:2IK
|
-0.018x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
Reliance Industrial Infrastructure Limited
NSE:RIIL
|
-0.028x |
|
Lang Inc
TW:6165
|
0.065x |
|
eGalax_eMPIA Technology
TWO:3556
|
0.066x |
|
Daewon Pharmaceutical Co. Ltd.
KO:003220
|
0.034x |
|
Ice Make Refrigeration Limited
NSE:ICEMAKE
|
-0.437x |
Annual Cash Flow Conversion Efficiency for Repare Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Repare Therapeutics Inc from 2018 to 2024. View RPTX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $151.13 Million | $-76.44 Million | -0.506x | +15.64% |
| 2023-12-31 | $212.08 Million | $-127.16 Million | -0.600x | -52146.58% |
| 2022-12-31 | $279.52 Million | $322.00K | 0.001x | +100.39% |
| 2021-12-31 | $288.42 Million | $-85.80 Million | -0.297x | -1302.41% |
| 2020-12-31 | $286.83 Million | $-6.08 Million | -0.021x | +89.66% |
| 2019-12-31 | $89.87 Million | $-18.43 Million | -0.205x | -136.38% |
| 2018-12-31 | $-22.38 Million | $-12.62 Million | 0.564x | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more